For all NGS testing from whole genomes and exomes to targeted panels
Fabric Genomics offers the leading AI-based platform for NGS analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing with best-in-class accuracy and scalability.Â
Dozens of the worlds leading hospitals, clinical labs, and academic centers such as Cincinnati Children’s, InterMountain, Rady Children’s Institute, LabCorp, and others count on Fabric AI technology and Fabric’s clinical services for their complete NGS software and services needs.Â
Co-Founder, President, and CEO
Dr. Reese is an internationally recognized expert and entrepreneur in Genomics and Bioinformatics. Prior to founding Fabric Genomics, Martin served as Vice President of Discovery Informatics for ValiGen, and co-founded Neomorphic, where he served as President and Chief Scientific Officer. The human genome annotation software that Martin developed at Neomorphic, provided the foundation for the successful commercialization of microarrays by Affymetrix. During his career he has been actively involved in community-wide assessments of genome annotation. He organized the state-of-the-art Genome Annotation Assessment Project and was a member of the Berkeley Drosophila Genome Project, which provided the essential proof-of-concept platform for “shotgun” sequencing technology. At the Lawrence Berkeley National Laboratories Martin developed gene-finding algorithms for the Human Genome Project. He holds a Masters degree in Medical Informatics from the University of Heidelberg and a Ph.D. in Genetics jointly from the University of Hohenheim, Germany and the University of California, Berkeley.
Co-Founder, President, Board Member, and CEO
Co-Founder, President, and CEO
Dr. Reese is an internationally recognized expert and entrepreneur in Genomics and Bioinformatics. Prior to founding Fabric Genomics, Martin served as Vice President of Discovery Informatics for ValiGen, and co-founded Neomorphic, where he served as President and Chief Scientific Officer. The human genome annotation software that Martin developed at Neomorphic, provided the foundation for the successful commercialization of microarrays by Affymetrix. During his career he has been actively involved in community-wide assessments of genome annotation. He organized the state-of-the-art Genome Annotation Assessment Project and was a member of the Berkeley Drosophila Genome Project, which provided the essential proof-of-concept platform for “shotgun” sequencing technology. At the Lawrence Berkeley National Laboratories Martin developed gene-finding algorithms for the Human Genome Project. He holds a Masters degree in Medical Informatics from the University of Heidelberg and a Ph.D. in Genetics jointly from the University of Hohenheim, Germany and the University of California, Berkeley.
Co-Founder, Chairman of the Board of Directors
Dr. Stuelpnagel currently serves as the Executive Chairman of Ariosa Diagnostic since 2009 and a board member at Sequenta, two leading genomic-based Diagnostic companies in the San Francisco bay area. Prior to this, John co-founded Illumina Inc., a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and biological function.
John was involved in making Illumina one of the most successful life science companies, serving as its first President and Chief Executive Officer from 1998 to 1999, Vice President of Business Development from 1999 to 2002, Senior Vice President of Operations from 2002 to 2005 and Chief Operating Officer from January 2005 to April 2008.
Prior, he was a venture capitalist at CW Group from 1997 to 1998 and with Catalyst Partners, a venture capital firm, from 1996 to 1997. While at CW Group, John uncovered what would become Illumina’s BeadArray technology at Tufts University and negotiated an exclusive license to that technology which led to the founding of Illumina Inc. He also served as a member of the Board of Directors of Illumina Inc. from April 1998 until April 2008. John received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles.
Co-Founder, Chairman of the Board of Directors
Co-Founder, Chairman of the Board of Directors
Dr. Stuelpnagel currently serves as the Executive Chairman of Ariosa Diagnostic since 2009 and a board member at Sequenta, two leading genomic-based Diagnostic companies in the San Francisco bay area. Prior to this, John co-founded Illumina Inc., a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and biological function.
John was involved in making Illumina one of the most successful life science companies, serving as its first President and Chief Executive Officer from 1998 to 1999, Vice President of Business Development from 1999 to 2002, Senior Vice President of Operations from 2002 to 2005 and Chief Operating Officer from January 2005 to April 2008.
Prior, he was a venture capitalist at CW Group from 1997 to 1998 and with Catalyst Partners, a venture capital firm, from 1996 to 1997. While at CW Group, John uncovered what would become Illumina’s BeadArray technology at Tufts University and negotiated an exclusive license to that technology which led to the founding of Illumina Inc. He also served as a member of the Board of Directors of Illumina Inc. from April 1998 until April 2008. John received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles.
Board Member
Co-Founder and Acting Chief Medical Officer
Dr. Billings serves as Chief Medical Officer at Fabric Genomics. Prior to joining Fabric Genomics, Dr. Billings was CMO at Life Technologies, acquired by Thermo Fisher Scientific, Inc. (NYSE: TMO). Before that he was founding and acting Director and Chief Scientific Officer of the Genomic Medicine Institute at El Camino Hospital. Dr. Billings served as President, CEO and Director of CELLective Dx Corporation. Dr. Billings currently serves on the Scientific Advisory Board of the FDA, the Genomic Medicine Advisory Committee at the Dept. of Veterans Affairs, and the National Academy of Sciences Institute of Medicine’s Roundtable on Genomics. He was Deputy Chief of Staff and Chief of General Medicine at the Palo Alto VA Healthcare System and Stanford Medical School, and then CMO and Deputy Network Director of VISN 17 in the Department of Veterans Affairs. He has been Professor of Anthropology (adjunct) at UC Berkeley and has published extensively on topics in immunology, genetics and medicine. Dr. Billings received an A.B. summa cum laude from UC San Diego, and both his M.D. and Ph.D. degrees from Harvard University.
Co-Founder & Acting Chief Medical Officer
Co-Founder and Acting Chief Medical Officer
Dr. Billings serves as Chief Medical Officer at Fabric Genomics. Prior to joining Fabric Genomics, Dr. Billings was CMO at Life Technologies, acquired by Thermo Fisher Scientific, Inc. (NYSE: TMO). Before that he was founding and acting Director and Chief Scientific Officer of the Genomic Medicine Institute at El Camino Hospital. Dr. Billings served as President, CEO and Director of CELLective Dx Corporation. Dr. Billings currently serves on the Scientific Advisory Board of the FDA, the Genomic Medicine Advisory Committee at the Dept. of Veterans Affairs, and the National Academy of Sciences Institute of Medicine’s Roundtable on Genomics. He was Deputy Chief of Staff and Chief of General Medicine at the Palo Alto VA Healthcare System and Stanford Medical School, and then CMO and Deputy Network Director of VISN 17 in the Department of Veterans Affairs. He has been Professor of Anthropology (adjunct) at UC Berkeley and has published extensively on topics in immunology, genetics and medicine. Dr. Billings received an A.B. summa cum laude from UC San Diego, and both his M.D. and Ph.D. degrees from Harvard University.
Chief Operating Officer and Clinical Director
Chief Operating Officer and Clinical Director
Dr. Hofherr serves as Chief Operating Officer and Clinical Director.
Prior to joining Fabric, Dr. Hofherr, served as Chief Scientific Officer of GeneDx. During his tenure, he led the shift to scalable exome and genome testing including rapid offerings for both, setting the path for the testing firm to become the leader in large scale clinical genomics. His background also includes building the Molecular Diagnostics program at Children’s National Hospital in Washington, DC.
Dr. Hofherr completed his clinical training in Molecular and Biochemical Genetics from the Mayo Clinic. He received his PhD from Baylor College of Medicine in Molecular and Human Genetics.
Vice President of Business Development
Vice President of Business Development
Dr. Vishnevetsky serves as Vice President of Business Development at Fabric Genomics with a focus on corporate partnerships and strategic alliances. Prior to joining Fabric Genomics Michael focused on Pharma engagement and companion diagnostics (CDx) test development, serving subsequently as a Head of Global Business Development at Personal Genome Diagnostics and Invivoscribe. Prior to that, Dr. Vishnevetsky held business development positions at Pacific Biosciences and Thermo Fisher Scientific with focus on utilization of molecular assays and next-generation sequencing (NGS) for diagnostics of rare disease and clinical oncology. Prior to that Dr. Vishnevetsky served and as Vice President of Sales and Marketing at WaferGen Biosystems and held sales management, marketing, and corporate strategy positions of increasing responsibility at Life Technologies-Invitrogen. Â
Dr. Vishnevetsky obtained a postdoctoral appointment in biology from the California Institute of Technology and holds a Ph.D. degree in Molecular Biology from Hebrew University of Jerusalem.Â
Vice President of Technology and Data ScienceÂ
VP, Technology and Data Science
Dr. Frise serves as VP, Technology and Data Science. Prior to joining Fabric, Erwin was a PI at the Berkeley Drosophila Genome Project at Lawrence Berkeley National Laboratories. Working closely with the statistics department at UC Berkeley, he pioneered new methods for low dimensional statistical representations for high dimensional data, image analysis and microscope automation. Earlier he was instrumental for the annotation of the first metazoan genome (Drosophila) by contributing analysis algorithms and developing one of the first high performance compute clusters for biological genome annotation.
Dr. Frise holds a Masters degree in Molecular Biology and a Ph.D. in Genetics jointly from University of Vienna, Austria and the University of California, San Francisco.
Vice President of Bioinformatics
Vice President of Bioinformatics
Dr. Kulp has spent over 30 years in bioinformatics and drug discovery informatics, with diverse experience in academia, contract research, public biotech and pharmaceuticals, and startups. Prior to joining Fabric, David was the Vice President of Research Informatics at Olema Oncology. Before that, he worked in genomics research at Harvard Medical School and the Broad Institute under Steve McCarroll. Among other appointments, David was an Assistant Professor of Computer Science at the University of Massachusetts Amherst, Vice President of Bioinformatics at Affymetrix, and Vice President of Research at Neomorphic. David received his Ph.D. under Dr. David Haussler at UC Santa Cruz, where he developed Genie, a protein-coding gene finder that was employed for the initial annotations of the drosophila, mouse, and human genomes.
Co-Founder, Fabric Genomics
University of Utah & USTAR Center for Genetic Discovery
Stanford University Cardiovascular Medicine & VIA Pharmaceuticals
University of Utah School of Medicine & Huntsman Cancer Institute
Institute for Basic Research in Developmental Disabilities (IBR)
Institute for Systems Biology & University of Washington
European Bioinformatics Institute
Discover how Fabric Genomics can help you succeed with NGS testing
